A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs ISTH 0036 (Primary)
  • Indications Open-angle glaucoma
  • Focus Adverse reactions; First in man
  • Sponsors Isarna Therapeutics
  • Most Recent Events

    • 28 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 15 May 2017 Results from this trial published in an Isarna Therapeutics Media Release.
    • 15 May 2017 According to an Isarna Therapeutics media release, data from this trial were presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top